denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: How Do We Enhance Results in Rare Hematologic Malignancies?
Hematology Disease Topics & Pathways:
Research, clinical trials, MDS, MPN, Clinical Research, Chronic Myeloid Malignancies, CMML, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Session: How Do We Enhance Results in Rare Hematologic Malignancies?
Hematology Disease Topics & Pathways:
Research, clinical trials, MDS, MPN, Clinical Research, Chronic Myeloid Malignancies, CMML, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Sunday, December 10, 2023, 9:30 AM-10:45 AM
Disclosures: Radia: Novartis: Consultancy, Speakers Bureau; Cogent Biosciences: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Member of study steering committees/ response adjudication committees for APEX/SUMMIT trials; Blueprint Medicines: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Member of study steering committees / response adjudication committee- EXPLORER and PATHFINDER Studies, Research Funding, Speakers Bureau.
OffLabel Disclosure: The use of Cladrabine in advanced systemic mastocytosis
See more of: How Do We Enhance Results in Rare Hematologic Malignancies?
See more of: Education Program
See more of: Education Program